RECEIVED

JUL 2 3 2001

TECH CENTER 1600/290 ATE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Docket No.: 44033-093

J. Peter KLEIN, et al.

Application No.: 09/544,984 : Group Art Unit: 1617

Filed: April 07, 2000 : Examiner: Mojdeh Bahar

For: THERAPEUTIC COMPOUNDS FOR INHIBITING INTERLEUKIN-12 SIGNALING

AND METHODS FOR USING SAME

RESPONSE TO RESTRICTION/ELECTION OF SPECIES REQUIREMENT

Assistant Commissioner for Patents Washington, DC 20231

Sir:

In response to the Office Action dated July 5, 2001, Applicants hereby elect Group I, corresponding to claims 1-18 and 29-36 for prosecution on the merits. The election is made with traverse because it is believed that a search for all of the pending claims can be made without a serious burden on the U.S. Patent and Trademark Office. The Examiner has further required an election of a single disclosed species. Applicants hereby elect the species wherein  $R_1$  is  $C_{(5-9)}$  hydroxyalkyl,  $R_2$  is methyl, X and Y are NH, and Z is  $C(R_3)$  where  $R_3$  is  $C_{(1-20)}$  alkylaminoalkyl. As acknowledged by the Examiner, it is believed that claims 1-46 are generic to the elected species.

Application No. 09/544,984

The above election of species is being made without traverse to extent that it is understood that (i) the requirement will be withdrawn upon the finding of an allowable genus and (ii) any species withdrawn from consideration will be transferred to the elected subject matter unless it is found patentably distinct from the elected or allowed claims.

Respectfully submitted,

McDERMOTT, WILL & EMERY

Cameron K. Weiffenbach Registration No. 44,488

600 13<sup>th</sup> Street, N.W. Washington, DC 20005-3096 202 756-8000

**Date: July 19, 2001** Facsimile: 202 756-8087